Latest Breaking News On - ஹான்ஸ் ஹெர்க்லாட்டுகள் - Page 1 : comparemela.com

(2) EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Miscellaneous Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros s license agreement with Checkmate Pharmaceuticals 15-Jul-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Article 53 of the SIX listing rules Schlieren (Zurich), Switzerland, 15 July, 2021 - Kuros Biosciences AG ( Kuros or the Company ), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing license agreement between Kuros and Checkmate Pharmaceuticals related to one o

United kingdomHans herklotsMichael grauKuros biosciencesGroup news serviceEqs groupInternational reporting standardSwiss exchangeCheckmate pharmaceuticalsChief executive officerஒன்றுபட்டது கிஂக்டம்ஹான்ஸ் ஹெர்க்லாட்டுகள்மைக்கேல் கிறௌகுழு செய்தி சேவைஈக்ஸ் குழுசர்வதேச புகாரளித்தல் தரநிலை